Pepaxto® (melphalan flufenamide) – Withdrawal from the U.S. market
October 22, 2021 - Oncopeptides announced the withdrawal of Pepaxto (melphalan flufenamide) following a clinical trial (OCEAN) that demonstrated an overall survival in the intention to treat population with a hazard ratio of 1.104.
Download PDF
